Status:
COMPLETED
Study of LW402 in Moderate-to-Severe Atopic Dermatitis
Lead Sponsor:
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Conditions:
Atopic Dermatitis (AD)
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.
Detailed Description
The study consists of an up-to-4-week screening period, a 12-week double-blind treatment period and a 4-week safety follow-up period.
Eligibility Criteria
Inclusion
- Diagnosed with AD for at least 12 months before Screening, with below requirements: 1) EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 at Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline
Exclusion
- Not enough washing-out period for previous therapy. Concurrent disease/status which may potentially affect the efficacy/safety judgement.
- pregnancy. Other.
Key Trial Info
Start Date :
May 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2025
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT07186387
Start Date
May 11 2023
End Date
February 13 2025
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China